563 related articles for article (PubMed ID: 1337507)
21. Lomefloxacin, a new fluoroquinolone. Studies on in vitro antimicrobial spectrum, potency, and development of resistance.
Aldridge KE; Henderberg A; Gebbia K; Schiro DD; Janney A; Sanders CV
Diagn Microbiol Infect Dis; 1989; 12(3):221-33. PubMed ID: 2791485
[TBL] [Abstract][Full Text] [Related]
22. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628.
Barrett MS; Jones RN; Erwin ME; Johnson DM; Briggs BM
Diagn Microbiol Infect Dis; 1991; 14(5):389-401. PubMed ID: 1665774
[TBL] [Abstract][Full Text] [Related]
23. In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.
Jones RN; Barrett MS; Erwin ME; Briggs BM; Johnson DM
Diagn Microbiol Infect Dis; 1991; 14(4):319-30. PubMed ID: 1909615
[TBL] [Abstract][Full Text] [Related]
24. In vitro activities of sparfloxacin, tosufloxacin, ciprofloxacin, and fleroxacin.
Barry AL; Fuchs PC
Antimicrob Agents Chemother; 1991 May; 35(5):955-60. PubMed ID: 1906696
[TBL] [Abstract][Full Text] [Related]
25. Susceptibility of 310 nonfermentative gram-negative bacteria to aztreonam, carumonam, ciprofloxacin, ofloxacin and fleroxacin.
Appelbaum PC; Spangler SK; Tamarree T
Chemotherapy; 1988; 34(1):40-5. PubMed ID: 3127127
[TBL] [Abstract][Full Text] [Related]
26. In vitro and in vivo evaluations of A-80556, a new fluoroquinolone.
Clement JJ; Tanaka SK; Alder J; Vojtko C; Beyer J; Hensey D; Ramer N; McDaniel D; Chu DT
Antimicrob Agents Chemother; 1994 May; 38(5):1071-8. PubMed ID: 8067740
[TBL] [Abstract][Full Text] [Related]
27. [In vitro activities of levofloxacin and other antibiotics against fresh clinical isolates].
Matsuzaki K; Koyama H; Chiba A; Omika K; Harada S; Sato Y; Hasegawa M; Kobayashi I; Kaneko A; Sasaki J
Jpn J Antibiot; 1999 Sep; 52(9):571-84. PubMed ID: 10746192
[TBL] [Abstract][Full Text] [Related]
28. In vitro antimicrobial activity of fluoroquinolones against clinical isolates obtained in 1989 and 1990.
Chen YC; Chang SC; Hsu LY; Hsieh WC; Luh KT
J Formos Med Assoc; 1993 Dec; 92(12):1040-8. PubMed ID: 7911351
[TBL] [Abstract][Full Text] [Related]
29. In vitro and in vivo antibacterial activities of E-4868, a new fluoroquinolone with a 7-azetidin ring substituent.
Guinea J; Robert M; Gargallo-Viola D; Xicota MA; Garcia J; Tudela E; Esteve M; Coll R; Pares M; Roser R
Antimicrob Agents Chemother; 1993 Apr; 37(4):868-74. PubMed ID: 8388202
[TBL] [Abstract][Full Text] [Related]
30. Antimicrobial activity of fluoroquinolones and other antibiotics on 1,116 clinical gram-positive and gram-negative isolates.
Mascellino MT; Farinelli S; Iegri F; Iona E; De Simone C
Drugs Exp Clin Res; 1998; 24(3):139-51. PubMed ID: 9825230
[TBL] [Abstract][Full Text] [Related]
31. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
[TBL] [Abstract][Full Text] [Related]
33. In-vitro activity of four new fluoroquinolones.
García-Rodríguez JA; García Sánchez JE; García García MI; Fresnadillo MJ; Trujillano I; García Sánchez E
J Antimicrob Chemother; 1994 Jul; 34(1):53-64. PubMed ID: 7961215
[TBL] [Abstract][Full Text] [Related]
34. In vitro activity of temafloxacin, a new difluoro quinolone antimicrobial agent.
Chin NX; Figueredo VM; Novelli A; Neu HC
Eur J Clin Microbiol Infect Dis; 1988 Feb; 7(1):58-63. PubMed ID: 3132380
[TBL] [Abstract][Full Text] [Related]
35. The in-vitro activity of Bay y 3118, a new chlorofluoroquinolone.
Wise R; Andrews JM; Brenwald N
J Antimicrob Chemother; 1993 Jan; 31(1):73-80. PubMed ID: 8383104
[TBL] [Abstract][Full Text] [Related]
36. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial.
Gootz TD; Brighty KE; Anderson MR; Schmieder BJ; Haskell SL; Sutcliffe JA; Castaldi MJ; McGuirk PR
Diagn Microbiol Infect Dis; 1994 Aug; 19(4):235-43. PubMed ID: 7851087
[TBL] [Abstract][Full Text] [Related]
38. In-vitro activity of WIN 57273 compared to the activity of other fluoroquinolones and two beta-lactam antibiotics.
Chin NX; Neu HC
J Antimicrob Chemother; 1991 Jun; 27(6):781-91. PubMed ID: 1657856
[TBL] [Abstract][Full Text] [Related]
39. In vitro evaluation of E-4695, a new fluoro-naphthyridine.
Jones RN
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):188-94. PubMed ID: 1327787
[TBL] [Abstract][Full Text] [Related]
40. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1994). I. Susceptibility distribution].
Kumamoto Y; Hirose T; Yokoo A; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Tazaki H; Iri H; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Kitagawa R; Igari J; Oguri T; Kosakai N; Yamaguchi K; Kashitani F; Yonezu S; Yamanaka Y; Takaha M; Iori F
Jpn J Antibiot; 1996 May; 49(5):465-93. PubMed ID: 8752862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
